Researchers at the École Polytechnique Fédérale de Lausanne (EPFL) have created the world’s first pill-sized bioprinter that can be swallowed and guided within the gastrointestinal (GI) tract to deposit bio-ink directly onto damaged tissues. This innovative device marks a major step toward non-invasive repair of internal injuries such as ulcers and hemorrhages.
Transforming the Treatment of GI Soft Tissue Injuries
Currently, soft tissue injuries of the GI tract—including ulcers or internal bleeding—require invasive surgical procedures that often do not ensure lasting repair. Bioprinting, which involves depositing biocompatible “ink” made from natural polymers like seaweed, has shown promise in tissue regeneration. However, existing bioprinting systems are typically bulky, invasive, and dependent on anesthesia.
In parallel, researchers have developed untethered medical technologies, such as smart capsules that deliver drugs to targeted sites through magnetic guidance. Yet, these devices struggle to maintain control when they come into contact with tissue walls, limiting their ability to perform precise interventions.
Introducing MEDS: A Pill-Sized Bioprinter
To overcome these limitations, EPFL’s Laboratory for Advanced Fabrication Technologies has developed MEDS (Magnetic Endoluminal Deposition System)—a miniature, magnetically guided bioprinter capable of performing tissue repair from within the body. Published in Advanced Science, this breakthrough could revolutionize minimally invasive medicine.
“By combining the principles of in-situ bioprinting with drug-release technologies used in smart capsules, we can envision a new class of device—a swallowable bioprinter,” said Prof. Vivek Subramanian, who leads the research team.
How the Device Works
MEDS functions much like a ballpoint pen, with a spring-loaded tip that releases bio-ink. However, it is miniaturized to the size of a pill and contains a small chamber filled with a living bio-gel. Instead of electronic components, the capsule’s release mechanism is activated by a near-infrared laser beam, which safely penetrates the body’s tissues to trigger the spring.
Once activated, the capsule can be precisely steered by an external magnet mounted on a robotic arm, allowing doctors to guide the device toward the target site and print tissue layers with exceptional accuracy.
Successful Laboratory and Animal Experiments
As reported by medicalxpress, the EPFL team tested MEDS in a series of simulated experiments, successfully repairing artificial ulcers and sealing simulated hemorrhages on gastric tissue models. In in-vivo trials conducted at an accredited U.S. animal research facility, the team demonstrated the capsule’s ability to deposit bio-ink in rabbit stomachs, tracked in real-time using X-ray fluoroscopy.
The researchers also showed that the capsule can be retrieved orally with magnetic guidance, confirming its safety and reusability for potential clinical applications.
Promising Results and Future Potential
Beyond serving as a protective layer over ulcers, the bio-ink can be infused with cells or therapeutic agents to promote healing. “In our lab experiments, the cell-laden bio-ink maintained its structure for over 16 days, acting as a micro-bioreactor capable of releasing growth factors and attracting new cells for wound healing,” explained Ph.D. student Sanjay Manoharan.
However, he cautioned that further in-vivo validation is needed. “Our findings establish the foundational role of MEDS in future bioprinting applications. We now aim to expand its use into blood vessels and abdominal wall tissues (peritoneum),” he added.
Toward a New Era of Non-Invasive Surgery
This pioneering technology represents a major milestone in the evolution of bioprinting and minimally invasive medicine. By merging precision robotics, biomaterials, and medical engineering, EPFL’s MEDS device could one day allow doctors to repair internal tissues without surgery, offering safer and faster recovery for patients.